{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:29:29Z","timestamp":1778873369701,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,11,24]],"date-time":"2006-11-24T00:00:00Z","timestamp":1164326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Diagnostic cytogenetic abnormalities are considered important prognostic factors in patients with acute myeloid leukaemia (AML). However, the prognostic assessments have mainly been derived from patients with AML aged &lt;60\u2003years. Two recent studies of AML patients of 60\u2003years and older proposed prognostic classifications with distinct discrepancies. To further study the prognostic value of cytogenetic abnormalities in this patient population, we have evaluated cytogenetic abnormalities in a series of 293 untreated patients with AML aged 60\u2003years and older, included in a randomised phase 3 trial, also in relation to patient characteristics and clinical outcome. The most frequently observed cytogenetic abnormality was trisomy 8 (+8), in 31 (11%) patients. Abnormalities, such as \u22125, 5q\u2010, abn(17p) and abn(17q), were almost exclusively present in complex karyotypes. A relatively favourable outcome was only observed in five patients with core\u2010binding factor abnormalities t(8;21) and inv(16)\/del(16)\/t(16;16). However, most of the other evaluated cytogenetic abnormalities, such as 5q\u2010, \u22127, +8, abn(17p), abn(17q), and complex aberrations expressed a more adverse prognosis when compared with patients with AML aged 60\u2003years and older with a normal karyotype. Large studies to confirm the prognosis of individual cytogenetic aberrations are warranted.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.06403.x","type":"journal-article","created":{"date-parts":[[2006,11,24]],"date-time":"2006-11-24T14:49:20Z","timestamp":1164379760000},"page":"96-105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60\u2003years and older express adverse prognostic value: results from a prospective clinical trial"],"prefix":"10.1111","volume":"136","author":[{"given":"Bronno","family":"Van Der Holt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri A.","family":"Breems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Berna Beverloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Van Den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan K.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"L\u00f6wenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,24]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Categorical Data Analysis","author":"Agresti A.","year":"1990"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(89)90025-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(84)80022-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11 <2191::AID-CNCR5>3.0.CO;2-L"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(84)80017-5"},{"key":"e_1_2_6_8_1","first-page":"1235","article-title":"Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine\u2010based chemotherapy: results from Cancer and Leukemia Group B 8461","volume":"4","author":"Byrd J.C.","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0772"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.813"},{"key":"e_1_2_6_11_1","first-page":"1491","article-title":"Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group","volume":"9","author":"Dastugue N.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290012074"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4354"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb00221.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-014324"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.10.3607"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1312"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1395"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_22_1","first-page":"403","article-title":"Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome","volume":"2","author":"Keating M.J.","year":"1988","journal-title":"Leukemia"},{"key":"e_1_2_6_23_1","first-page":"2952","article-title":"Use of recombinant GM\u2010CSF during and after remission induction chemotherapy in patients aged 61\u2003years and older with acute myeloid leukemia: final report of AML\u201011, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato\u2010Oncology Cooperative Group","volume":"90","author":"Lowenberg B.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_24_1","volume-title":"ISCN (1995): An International System for Human Cytogenetic Nomenclature","author":"Mitelman F.","year":"1995"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00040-7"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199712)56:4<224::AID-AJH5>3.0.CO;2-Z"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.263.263"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4473257.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4075"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(93)90040-S"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322503"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(94)90174-0"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03043.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2307\/3001968"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.29"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.06403.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.06403.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:43:02Z","timestamp":1697427782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.06403.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1365-2141.2006.06403.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06403.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,24]]},"assertion":[{"value":"2006-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}